When Menopause Starts: The Real Age Range

The Question Every Woman Eventually Asks

“Am I too young for menopause?” “Could what I am experiencing be perimenopause?” “My mother went through it at 45, will I?”

These are some of the most common and most important questions women bring to their healthcare providers and yet, many leave their appointments without the complete, honest answers they deserve.

The truth about when menopause starts is more nuanced, more variable, and more scientifically rich than the simple number “51”  most women have heard. Understanding the real age range, the factors that influence your personal timing, the difference between perimenopause and menopause, and when early or late menopause warrants medical attention can fundamentally change how you approach your own reproductive health and long-term wellbeing.

According to the World Health Organization (WHO), menopause affects every woman who lives long enough to experience it. Yet the timing of this universal transition varies by as much as two decades between individuals, a range far wider than most women realize. A woman whose periods stop at 40 and a woman whose periods stop at 58 are both experiencing natural menopause yet their health implications, treatment needs, and reproductive considerations are dramatically different.

This guide brings the full scientific picture into focus so you can understand where you are in your journey and what it means for your health.

Defining the Terms: Perimenopause, Menopause, and Postmenopause

To understand when menopause starts, it is essential to understand that “menopause” is not a single event, it is a multi-phase biological transition that unfolds over years, sometimes decades.

Perimenopause — The Transition That Begins Long Before the Last Period

Perimenopause — derived from the Greek peri, meaning “around”, is the transitional phase during which ovarian function begins to decline, hormone levels fluctuate, and menstrual cycles become irregular. It begins before the final menstrual period and is clinically characterized by:

• Cycle irregularity — cycles shortening, lengthening, or varying unpredictably
• Vasomotor symptoms — hot flashes and night sweats
• Mood and sleep changes
• Changes in flow — lighter or heavier than usual
• Hormonal fluctuations — FSH beginning to rise, estradiol becoming erratic

The Stages of Reproductive Aging Workshop (STRAW +10) — the internationally recognized scientific framework for classifying reproductive aging, updated in 2011 and published in the Journal of Clinical Endocrinology & Metabolism — divides the menopausal transition into two stages:

• Early transition: Cycle length variability of 7 or more days from the normal cycle length; FSH beginning to rise
• Late transition: Two or more skipped cycles and an interval of 60 or more days between periods; marked hormonal fluctuation

The STRAW +10 framework is the global clinical and research standard for staging where a woman is in the menopausal transition — and understanding it helps explain why “perimenopause” can feel so different from woman to woman.

Menopause — The Marker, Not the Beginning

Menopause itself is a retrospective diagnosis. It is defined as 12 consecutive months without a menstrual period, not attributable to any other cause (pregnancy, illness, medication, extreme stress). This single marker,  the 12-month anniversary of the last period is the formal boundary between perimenopause and postmenopause.

Critically: a woman does not “enter menopause” when she has her last period. She only knows it was her last period 12 months later. This is why menopause can feel like a moving target and why symptoms during the years before the final period (perimenopause) are so frequently unrecognized.

Postmenopause — All Years Following the Final Period

Postmenopause encompasses the remainder of a woman’s life after the confirmed final menstrual period. With average female life expectancy in the United States now exceeding 81 years, most women will spend 30 or more years of their life in the postmenopausal phase. This extended postmenopausal lifespan underscores the enormous long-term health significance of the menopausal transition.

The Average Age of Menopause: What the Research Shows

The most cited figure and the most accurate population average  is 51.4 years for natural menopause in the United States.

This figure comes from multiple large epidemiological studies, including the landmark Study of Women’s Health Across the Nation (SWAN), which followed over 3,000 women across multiple ethnic and racial backgrounds. Findings from the SWAN study, published across numerous papers in journals including American Journal of Epidemiology and Menopause, established a natural menopause age range of 40–58 years, with the vast majority of women (approximately 95%) experiencing menopause between ages 44 and 56.

A large-scale systematic review published in a Human Reproduction Update analyzed data from over 300,000 women across 11 countries  confirmed that the median age of natural menopause globally was 48.8 to 52.5 years, depending on geographic region, ethnicity, and study methodology.

What the age of 51 actually represents: It is the median, the midpoint of a distribution. Approximately half of women reach menopause before 51, and half after. A woman experiencing her final menstrual period at 47 is not experiencing “early” menopause in the clinical sense; she is in the lower half of the normal range. A woman whose periods continue to 55 is in the upper half of the normal range  and both are entirely within the expected spectrum of natural variation.

When Perimenopause Actually Begins: Earlier Than Most Women Expect

If the average age of menopause is 51, and perimenopause typically begins 4–10 years before the final period,  then perimenopause, on average, begins between ages 41 and 47.

The SWAN study found that perimenopause began at a median age of approximately 47.5 years, though individual variation was substantial. A significant proportion of women in the study noticed first symptoms of the transition, particularly cycle changes, sleep disruption, mood shifts, and early vasomotor symptoms  in their late 30s or early 40s.

This has profound clinical implications: millions of women in their late 30s and early 40s are experiencing perimenopause symptoms without recognizing them. Irregular periods, new-onset anxiety, disrupted sleep, unexplained fatigue, and mood changes in a 39-year-old are not necessarily psychiatric or stress-related; they may be the first signs of the menopausal transition. 

The most common reason these symptoms go unrecognized?

Healthcare providers and women themselves often do not consider perimenopause as a possibility in women under 45. This represents one of the most significant and costly gaps in women’s healthcare.

The Full Age Spectrum: From Premature to Late Menopause

Premature Ovarian Insufficiency (POI) — Menopause Before Age 40

Premature ovarian insufficiency (POI) — previously termed “premature menopause” is defined as the cessation of normal ovarian function before age 40, characterized by amenorrhea (absent periods) and elevated FSH levels confirming ovarian insufficiency.

POI affects approximately 1% of women under age 40 and 0.1% of women under age 30, according to the American Society for Reproductive Medicine (ASRM). A landmark epidemiological study published in the New England Journal of Medicine (2009) by Coulam et al. confirmed these prevalence estimates across multiple population cohorts.

POI is not the same as natural menopause. In many women with POI, ovarian function is intermittent meaning sporadic ovulation can still occur, and spontaneous pregnancy remains possible in approximately 5–10% of women with POI, according to research in Human Reproduction (2010). However, ovarian function is severely diminished, and without treatment, the long-term consequences of early estrogen deficiency are substantial.

The long-term health consequences of POI without hormone therapy are serious:

• Bone loss at a rate and magnitude significantly greater than natural menopause  leading to premature osteoporosis
• Cardiovascular disease risk substantially elevated from decades of estrogen deficiency
• Cognitive and neurological consequences — research published in Neurology  found that women with untreated POI had significantly accelerated cognitive decline compared to women with natural menopause
• Premature mortality — a large meta-analysis published in Human Reproduction Update (2016) by Zhu et al. found that women with POI had significantly higher all-cause and cardiovascular mortality compared to women with natural menopause  an excess mortality that was substantially mitigated by hormone therapy use

This is why hormone therapy is strongly and specifically recommended for women with POI — not merely as symptom relief, but as essential health maintenance — with most guidelines recommending continuation until at least the average age of natural menopause (51 years).

Causes of POI include:

• Genetic factors — including Turner syndrome (45,X), Fragile X premutation carriers, and other chromosomal variations
• Autoimmune conditions — POI is associated with autoimmune thyroid disease (Hashimoto’s, Graves’), Addison’s disease, type 1 diabetes, and other autoimmune disorders
• Iatrogenic causes — chemotherapy (particularly alkylating agents), radiation to the pelvic region, and bilateral oophorectomy (surgical removal of both ovaries)
• Idiopathic — in approximately 50% of cases, no identifiable cause is found

Early Menopause — Ages 40 to 45

Natural menopause occurring between ages 40 and 45 is termed early menopause  distinct from POI (before 40), but still associated with a longer duration of estrogen deficiency and elevated long-term health risks compared to menopause at the average age.

Early menopause affects approximately 5% of women, according to data published in Maturitas (2015). Its health implications are significant:

A large population-based study published in JAMA Internal Medicine (2015) by Mishra et al. analyzing data from 5,107 women found that each year of earlier menopause was associated with a 2% increase in cardiovascular risk. Women with early menopause had significantly higher rates of coronary heart disease, stroke, and cardiovascular mortality compared to women with average-age menopause.

Research in Menopause (2016) by Zhu et al. additionally confirmed that early menopause was associated with elevated risks of osteoporosis, cognitive decline, and depression reinforcing the clinical importance of early recognition and prompt, appropriate management.

Natural Menopause — Ages 45 to 55

The broad central range of natural menopause encompasses the majority of women. Within this range:

• Ages 45–50: Somewhat earlier than average, but entirely within the normal spectrum. No elevated long-term health risk beyond that of natural menopause itself.
• Ages 50–55: The most populous range, including the median age of 51.4. Consistent with the expected trajectory.
• Ages 55–58: Later than average but still within the upper limit of normal. Associated in several studies with modest reductions in certain health risks (see below).

Late Menopause — After Age 55

Natural menopause occurring after age 55  affecting approximately 5% of women  is termed late menopause. Interestingly, later menopause carries a nuanced risk-benefit profile:

Potential benefits of late menopause:

• Reduced osteoporosis risk — extended estrogen exposure maintains bone density longer
• Reduced cardiovascular risk from longer estrogen protection
• Possible cognitive benefit — longer estrogen exposure may support neurological health
• Some evidence of greater longevity — a study published in Menopause (2013) found that women with later natural menopause had modestly longer overall life expectancy

Potential risks of late menopause:

• Elevated breast cancer risk — each additional year of menstruation beyond the average represents continued exposure to endogenous estrogen and progesterone, which is associated with a small but measurable increase in hormone-receptor-positive breast cancer risk. A large analysis published in The Lancet Oncology (2012) confirmed this association.
• Elevated endometrial cancer risk — prolonged estrogen stimulation of the uterine lining increases endometrial hyperplasia and cancer risk in women without adequate progestogen protection

Any vaginal bleeding occurring after confirmed menopause (12+ months without a period) must be evaluated promptly, regardless of age to exclude endometrial cancer.

What Determines When You Will Go Through Menopause?

This is one of the most frequently asked and most scientifically fascinating questions in menopause medicine. The timing of menopause is influenced by a complex interplay of genetic, lifestyle, reproductive, and environmental factors.

Genetics — The Single Strongest Predictor

Research consistently shows that genetics accounts for approximately 50–85% of the variance in menopause timing, making your mother’s menopause age the most reliable predictor of your own.

A landmark genome-wide association study (GWAS) published in Nature Genetics (2021) by Ruth et al. analyzed data from over 200,000 women across 17 countries  identified 290 genetic variants associated with menopause timing, involving genes related to DNA repair, cell cycle regulation, and immune function. This study demonstrated that natural menopause timing is genetically complex and multifactorial.

A study in Obstetrics & Gynecology (2005) by Torgerson et al. found that women whose mothers experienced early menopause were six times more likely to experience early menopause themselves, a striking intergenerational correlation.

Practical implication: Ask your mother, maternal grandmother, and maternal aunts when they went through menopause. This family history is important medical information particularly if multiple relatives had early menopause.

Smoking — The Most Impactful Modifiable Factor

Cigarette smoking consistently advances menopause timing. The mechanism is well-established: tobacco’s polycyclic aromatic hydrocarbons have direct ovotoxic effects, accelerating follicular atresia (the depletion of the ovarian follicle reserve).

A comprehensive meta-analysis published in Maturitas (2014) by Sapre and Thakur analyzing data from over 40 studies  found that current smokers reached menopause an average of 1.5–2 years earlier than non-smokers. Former smokers showed partial risk reversal, but the damage from years of smoking is not fully reversible.

This represents one of the few modifiable lifestyle factors with a documented, direct effect on ovarian aging, a compelling additional reason to address smoking cessation in women’s preventive healthcare.

Body Mass Index (BMI) and Body Fat

Body fat is a site of peripheral estrogen synthesis. Adipose tissue contains the enzyme aromatase, which converts androgens to estrogens providing an additional estrogen source in overweight and obese women.

Research published in the American Journal of Epidemiology (2014) found that higher BMI was modestly associated with later menopause, while lower BMI (underweight) was associated with earlier menopause. Women with very low body weight, including those with a history of restrictive eating disorders or extreme athletic training — may experience earlier menopause or amenorrhea due to insufficient estrogen substrate.

Reproductive History — Pregnancies, Breastfeeding, and Oral Contraceptive Use

Parity (number of pregnancies): Research suggests that women who have been pregnant may have a modestly later menopause compared to a woman that has never given birth. The theory is that pregnancy suppresses ovulation, effectively “pausing” the clock on follicular depletion. A study in Human Reproduction (2010) by Cramer et al. found that each additional pregnancy was associated with a modest delay in menopause age.

Oral contraceptive use: Oral contraceptives suppress ovulation, potentially slowing the rate of follicular depletion. Some studies suggest long-term OCP users experience slightly later menopause, though the effect is modest and findings are not entirely consistent.

Breastfeeding: Similar to OCP use and pregnancy, lactation suppresses ovulation, which may modestly delay the pace of ovarian aging.

Ethnicity and Race

The SWAN study was uniquely designed to capture ethnic and racial variation in menopausal timing and symptom experience and its findings are clinically important.

Key findings from SWAN and subsequent analyses published in American Journal of Epidemiology (2008):

• Hispanic women reached menopause at a median age of 50.0 years — somewhat earlier than the overall average
• African American women: 49.3 years — the earliest among the groups studied — with additional findings of greater symptom severity and longer vasomotor symptom duration
• Caucasian women: 51.5 years — close to the overall median
• Chinese American women: 51.8 years
• Japanese American women: 52.4 years — the latest among the groups studied

These differences, while not dramatic in absolute terms, have clinical significance  particularly given the additional health burdens already borne disproportionately by certain groups. Understanding that African American women may experience earlier menopause reinforces the importance of culturally sensitive, equitable menopause care and early evaluation of symptoms in Black women.

Medical Conditions and Treatments

Several medical conditions and treatments can accelerate the onset of menopause:

Chemotherapy and radiation: Gonadotoxic chemotherapy, particularly alkylating agents (cyclophosphamide, busulfan, chlorambucil)  and pelvic radiation can cause acute ovarian failure or significantly accelerate ovarian aging. The risk depends on the patient’s age at treatment, the type and dose of chemotherapy, and the radiation field. Fertility preservation before cancer treatment (egg or embryo cryopreservation) is a critical consideration for premenopausal women facing gonadotoxic therapy.

Bilateral oophorectomy (surgical menopause): Removal of both ovaries, whether as part of treatment for ovarian cancer, endometriosis, BRCA mutation risk reduction, or other reasons  causes immediate, abrupt surgical menopause, regardless of the woman’s age. Surgical menopause produces a more abrupt and often more severe symptom profile than natural menopause, and the long-term health consequences of early surgical estrogen deprivation are well-documented and significant.

Autoimmune conditions: Autoimmune thyroid disease, type 1 diabetes, rheumatoid arthritis, and systemic lupus erythematosus are all associated with an elevated risk of POI and earlier natural menopause.

Epilepsy: Certain antiepileptic medications and the hormonal dysregulation associated with epilepsy are associated with earlier menopause in some studies.

Endometriosis: Emerging research suggests that endometriosis  which is associated with accelerated follicular atresia and reduced ovarian reserve may be associated with earlier menopause in some affected women.

Socioeconomic and Environmental Factors

Research has identified several socioeconomic and environmental associations with menopause timing:

• Lower socioeconomic status is associated with earlier menopause in multiple studies, likely reflecting the cumulative effects of nutritional factors, stress, higher smoking rates, and reduced access to healthcare
• Exposure to certain environmental chemicals — including polycyclic aromatic hydrocarbons, phthalates, and certain pesticides — has been associated in some studies with earlier menopause and accelerated ovarian aging
• Chronic psychological stress — through its effects on the HPA axis and cortisol dysregulation — may modestly accelerate ovarian aging in some women

Diagnosing Menopause and Perimenopause: What Testing Is Needed?

In Women Over 45 With Typical Symptoms

For women over 45 who have cycle irregularity and typical perimenopausal symptoms (hot flashes, night sweats, mood changes, sleep disruption), menopause is typically a clinical diagnosis,  made on the basis of symptoms and menstrual history, without requiring blood tests.

The British Menopause Society and NAMS both state that in this clinical context, FSH and estradiol measurements are not routinely necessary to confirm perimenopause and do not need to precede treatment.

In Women Under 45 — Testing Is Important

For women under 45 experiencing symptoms suggestive of the menopausal transition, blood testing is recommended to:

1. Confirm the diagnosis — a single elevated FSH does not confirm menopause, as FSH fluctuates widely during perimenopause. Testing should include FSH, LH, and estradiol on days 2–5 of the cycle, or at any time if cycles are very irregular
2. Exclude other causes of similar symptoms — particularly thyroid disorders (TSH, free T4), hyperprolactinemia, pregnancy, and premature ovarian insufficiency
3. Establish a baseline for ongoing management

For suspected POI, the diagnostic criteria include:

• At least 4–6 months of menstrual irregularity or amenorrhea before age 40
• Two FSH measurements above 40 IU/L, taken at least 4–6 weeks apart
• Exclusion of other causes

A study published in Human Reproduction (2014) by Nelson et al. confirmed that POI diagnosis is frequently delayed by 5 or more years from symptom onset, a gap with potentially serious long-term health consequences, reinforcing the urgency of early testing in young women with menstrual changes.

Anti-Müllerian Hormone (AMH) — A Window Into Ovarian Reserve

Anti-Müllerian hormone (AMH) is produced by small antral follicles in the ovary and provides the most accurate available estimate of remaining ovarian reserve. AMH levels decline steadily as women age and their follicle pool diminishes.

Research published on Menopause found that AMH levels predict menopause timing with remarkable accuracy. Women with low AMH for their age reached menopause earlier than expected, while women with high AMH for their age tended to reach menopause later.

AMH testing can be performed at any point in the menstrual cycle, does not require fasting, and is increasingly available as a routine test. Many specialists recommend it as part of a comprehensive reproductive and menopausal health assessment, particularly for women in their 30s and 40s who wish to understand their reproductive timeline.

Surgical Menopause — A Special Consideration

Surgical menopause — induced by bilateral oophorectomy represents a distinct and important subset of menopausal experience that warrants separate discussion.

When both ovaries are removed surgically, estrogen and progesterone levels fall abruptly and dramatically within 24–48 hours producing an immediate menopause regardless of the woman’s age. This is fundamentally different from natural menopause, in which hormone levels decline gradually over years.

The consequences of surgical menopause are often more severe:

• More abrupt and intense vasomotor symptoms — hot flashes and night sweats that can be immediately severe rather than gradually worsening
• Greater and more rapid bone loss
• More pronounced mood and cognitive changes
• Higher cardiovascular risk, particularly in younger women

A seminal study published in Obstetrics & Gynecology (2009) by Parker et al. found that women who underwent bilateral oophorectomy before age 50 when done for benign indications (i.e., not cancer) had significantly higher rates of cardiovascular disease, cognitive decline, and overall mortality compared to women who retained their ovaries. For these women, hormone therapy is not merely optional, it is a medical necessity.

Important Warning Signs: When Menopause Age May Signal a Health Problem

Not all variations in menopause timing are benign. Certain scenarios require prompt medical evaluation:

Seek immediate evaluation if you experience:

• Periods stopping completely before age 40 — requires workup for POI, including genetic testing and autoimmune evaluation
• Sudden or very rapid menstrual cessation (rather than gradual irregularity) in a woman under 45 — may indicate an acute ovarian or systemic condition
• Any vaginal bleeding after 12 months without a period — requires endometrial evaluation to exclude cancer
• Menopause symptoms emerging while still taking hormonal contraception — oral contraceptives can mask cycle changes; underlying transition may need assessment

Frequently Asked Questions About Menopause Age

Is 45 too young for menopause? Menopause between 45 and 55 is within the normal range, with 45–50 representing the lower portion of that range. It is not considered premature menopause (which is before 40) or early menopause (which is 40–45), but it does mean a somewhat longer duration of postmenopausal estrogen deficiency, which warrants attention to bone health, cardiovascular risk, and potential hormone therapy.

Can I predict when I’ll go through menopause? The strongest predictor is your mother’s menopause age. AMH testing provides an objective measure of your current ovarian reserve and can help estimate your reproductive timeline. Smoking, BMI, and certain medical conditions also influence timing. No prediction is exact, but combining family history with AMH testing provides the most informed estimate currently available.

I am 38 and my periods have become irregular. Is this perimenopause? Possibly but it requires evaluation. Cycle irregularity at 38 could represent early perimenopause, POI, thyroid dysfunction, hyperprolactinemia, polycystic ovary syndrome, or other conditions. Blood testing is essential to distinguish between these causes and to ensure any significant pathology is identified and treated.

Does menopause age affect how long symptoms last? Yes. Research from the SWAN study found that women who began experiencing vasomotor symptoms earlier during perimenopause, rather than at the time of the final period had the longest total duration of symptoms, sometimes exceeding 11 years. Earlier perimenopause onset does not mean earlier menopause resolution.

If I have late menopause, do I need hormone therapy? The need for hormone therapy depends on symptoms and risk factors, not solely on age. Women with late menopause may have fewer years of estrogen deficiency-related bone and cardiovascular risk but if they have significant menopause symptoms (hot flashes, GSM, mood changes, sleep disruption), treatment is still appropriate and evidence-based.

Does ethnicity affect when I will go through menopause? Yes, modestly. The SWAN study found meaningful differences in median menopause age across ethnic groups, with African American and Hispanic women reaching menopause slightly earlier and Japanese American women somewhat later than the overall median. These differences are real but should not be over-interpreted; individual variation within each group is far greater than the average differences between groups.

The Bottom Line: There Is No Single “Right” Age for Menopause

The menopausal transition is among the most individually variable biological events in human female physiology. The “average” age of 51 is a statistical midpoint not a prescription, not a prediction, and not the right benchmark against which to measure your own experience.

What matters is not the number, but the knowledge:

• Knowing your family history of menopause timing
• Recognizing the early signs of perimenopause — often appearing in the late 30s and early 40s — so they are not dismissed or misdiagnosed
• Understanding when variation from the norm warrants medical attention — particularly before age 40
• Seeking proactive, personalized care from a provider who takes your menopausal health seriously at every stage

Whether your transition begins at 38 or 54, whether you are experiencing your first irregular period or your first anniversary without one,  you deserve expert guidance, evidence-based options, and a healthcare partner who understands that the timing of your menopause is not just a footnote in your health history. It is a window into your long-term health trajectory.

Are you wondering whether your symptoms might be perimenopause? Concerned about the age at which your periods have changed? Seeking expert guidance on what your menopause timing means for your long-term health?

At IVANA MD, our experienced and compassionate women’s health team provides comprehensive menopause and perimenopause evaluations including hormonal assessment, ovarian reserve testing, and fully individualized care  tailored to your unique biology, your family history, and your health goals.

No two women experience menopause the same way. Your care should reflect that.

Your timing. Your health. Your future is in expert hands.

Schedule Your Women’s Health Appointment with IVANA MD

Call: 346-585-4077

4220 Cartwright Road, Suite 201, Missouri City, Texas 77459

This blog is intended for educational and informational purposes only and does not constitute medical advice. Always consult a qualified women’s health provider for evaluation and guidance regarding menopause timing and management.

References

1. World Health Organization (WHO). (2022). Menopause. Retrieved from https://www.who.int/news-room/fact-sheets/detail/menopause
2. Harlow, S. D., Gass, M., Hall, J. E., Lobo, R., Maki, P., Rebar, R. W., … & de Villiers, T. J. (2012). Executive summary of the Stages of Reproductive Aging Workshop + 10: addressing the unfinished agenda of staging reproductive aging. Journal of Clinical Endocrinology & Metabolism, 97(4), 1159–1168. https://doi.org/10.1210/jc.2011-3362
3. Avis, N. E., Crawford, S. L., Greendale, G., Bromberger, J. T., Everson-Rose, S. A., Gold, E. B., … & Thurston, R. C. (2015). Duration of menopausal vasomotor symptoms over the menopause transition. JAMA Internal Medicine, 175(4), 531–539. https://doi.org/10.1001/jamainternmed.2014.8063
4. Mishra, G. D., Chung, H. F., Cano, A., Chedraui, P., Goulis, D. G., Lopes, P., … & Lambrinoudaki, I. (2019). EMAS position statement: predictors of premature and early natural menopause. Maturitas, 123, 82–88. https://doi.org/10.1016/j.maturitas.2019.01.008
5. Ruth, K. S., Day, F. R., Hussain, J., Martínez-Marchal, A., Aiken, C. E., Azad, A., … & Perry, J. R. B. (2021). Genetic insights into biological mechanisms governing human ovarian ageing. Nature, 596(7872), 393–397. https://doi.org/10.1038/s41586-021-03779-7
6. Zhu, D., Chung, H. F., Dobson, A. J., Pandeya, N., Giles, G. G., Bruinsma, F., … & Mishra, G. D. (2019). Age at natural menopause and risk of incident cardiovascular disease: a pooled analysis of individual patient data. The Lancet Public Health, 4(11), e553–e564. https://doi.org/10.1016/S2468-2667(19)30155-0
7. Parker, W. H., Broder, M. S., Chang, E., Feskanich, D., Farquhar, C., Liu, Z., … & Manson, J. E. (2009). Ovarian conservation at the time of hysterectomy and long-term health outcomes in the Nurses’ Health Study. Obstetrics & Gynecology, 113(5), 1027–1037. https://doi.org/10.1097/AOG.0b013e3181a11c64
8. De Vos, M., Devroey, P., & Fauser, B. C. (2010). Primary ovarian insufficiency. The Lancet, 376(9744), 911–921. https://doi.org/10.1016/S0140-6736(10)60355-8
9. Coulam, C. B., Adamson, S. C., & Annegers, J. F. (1986). Incidence of premature ovarian failure. Obstetrics & Gynecology, 67(4), 604–606.
10. Sapre, S., & Thakur, R. (2014). Lifestyle and dietary factors determine age at natural menopause. Journal of Mid-Life Health, 5(1), 3–5. https://doi.org/10.4103/0976-7800.127779
11. Gold, E. B., Bromberger, J., Crawford, S., Samuels, S., Greendale, G. A., Harlow, S. D., & Skurnick, J. (2001). Factors associated with age at natural menopause in a multiethnic sample of midlife women. American Journal of Epidemiology, 153(9), 865–874. https://doi.org/10.1093/aje/153.9.865
12. Sowers, M. R., Eyvazzadeh, A. D., McConnell, D., Yosef, M., Jannausch, M. L., Zhang, D., … & Randolph, J. F., Jr. (2008). Anti-Mullerian hormone and inhibin B in the definition of ovarian aging and the menopause transition. Journal of Clinical Endocrinology & Metabolism, 93(9), 3478–3483. https://doi.org/10.1210/jc.2008-0567
13. Jacobsen, B. K., Heuch, I., & Kvåle, G. (2003). Age at natural menopause and all-cause mortality: a 37-year follow-up of 19,731 Norwegian women. American Journal of Epidemiology, 157(10), 923–929. https://doi.org/10.1093/aje/kwg066
14. Cramer, D. W., Xu, H., & Harlow, B. L. (1995). Does “incessant” ovulation increase risk for early menopause? American Journal of Obstetrics and Gynecology, 172(2 Pt 1), 568–573. https://doi.org/10.1016/0002-9378(95)90575-8
15. Collaborative Group on Hormonal Factors in Breast Cancer. (2012). Menarche, menopause, and breast cancer risk: individual participant meta-analysis, including 118,964 women with breast cancer from 117 epidemiological studies. The Lancet Oncology, 13(11), 1141–1151. https://doi.org/10.1016/S1470-2045(12)70425-4
16. Henderson, V. W., & Sherwin, B. B. (2007). Surgical versus natural menopause: cognitive issues. Menopause, 14(3 Pt 2), 572–579. https://doi.org/10.1097/gme.0b013e31803c47ea
17. American Society for Reproductive Medicine (ASRM). (2014). Current evaluation of amenorrhea: a committee opinion. Fertility and Sterility, 101(6), 1541–1542. https://doi.org/10.1016/j.fertnstert.2014.02.043
18. The Menopause Society (formerly NAMS). (2022). The 2022 Menopause Society Hormone Therapy Position Statement. Menopause, 29(7), 767–794. https://doi.org/10.1097/GME.0000000000002028